{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "208 patients were randomized in a 1:1 ratio"
      },
      "Participants": {
        "score": 1,
        "evidence": "high-risk patients with heart failure and FMR"
      },
      "Intervention": {
        "score": 2,
        "evidence": "M-TEER with MitraClip device or surgical mitral valve repair or replacement"
      },
      "Objective": {
        "score": 1,
        "evidence": "The MATTERHORN trial aimed to compare the efficacy and safety outcomes"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "At 1 year, at least one primary endpoint event"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "208 patients were randomized in a 1:1 ratio"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "208 patients were randomized in a 1:1 ratio"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "16.7% of the M-TEER group and 22.5% of the surgery group"
      },
      "Harms": {
        "score": 1,
        "evidence": "41.0% of the patients in the intervention group and 77.3% in the surgery group had at least one adverse event"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}